A Multicentre, Retrospective, Non-interventional Review of Electronic Prescribing Records of Any Second-line (2L) Patients and Chart Notes of 2L Cabozantinib Patients, Investigating the Treatment Sequence Pathway Following a First-line, Immuno-oncology Checkpoint Inhibitor (1L IO) Containing Combination Therapy in Patients With Advanced Renal Cell Carcinoma (aRCC) (CARINA)
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Cabozantinib (Primary) ; Avelumab; Axitinib; Ipilimumab; Nivolumab; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CARINA
- Sponsors Ipsen
- 18 Feb 2023 Interim Results(n=129) assessing treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy presented at the 2023 Genitourinary Cancers Symposium
- 30 Jun 2022 Status changed from recruiting to completed.
- 25 Nov 2021 Planned End Date changed from 30 Oct 2022 to 31 Oct 2022.